Agilent Technologies, Inc. (NYSE:A) shares hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $65.21 and last traded at $65.16, with a volume of 646,999 shares. The stock had previously closed at $64.71.

A has been the topic of several research analyst reports. Zacks Investment Research raised Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 price objective on the stock in a research note on Tuesday, May 16th. Deutsche Bank AG upped their target price on Agilent Technologies from $58.00 to $62.00 and gave the stock a “buy” rating in a report on Monday, May 22nd. Cowen and Company upped their target price on Agilent Technologies from $53.00 to $62.00 and gave the stock a “market perform” rating in a report on Tuesday, May 23rd. Jefferies Group LLC upped their target price on Agilent Technologies from $59.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, May 23rd. Finally, Robert W. Baird upped their target price on Agilent Technologies from $57.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, May 24th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $63.18.

The company’s 50 day moving average is $61.42 and its 200 day moving average is $57.39. The firm has a market capitalization of $20.98 billion, a PE ratio of 33.59 and a beta of 1.30.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Tuesday, August 15th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.07. Agilent Technologies had a net margin of 14.36% and a return on equity of 16.95%. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the previous year, the company earned $0.49 EPS. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. Equities research analysts expect that Agilent Technologies, Inc. will post $2.32 earnings per share for the current year.

In related news, Director Boon Hwee Koh sold 4,500 shares of the business’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $63.63, for a total value of $286,335.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Patrick Kaltenbach sold 5,000 shares of the business’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $61.26, for a total transaction of $306,300.00. Following the completion of the sale, the insider now directly owns 45,138 shares of the company’s stock, valued at $2,765,153.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 141,098 shares of company stock valued at $8,798,933.

A number of institutional investors and hedge funds have recently made changes to their positions in A. Balentine LLC raised its holdings in shares of Agilent Technologies by 2.9% in the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock valued at $106,000 after buying an additional 50 shares during the last quarter. Sun Life Financial INC raised its holdings in shares of Agilent Technologies by 26,144.4% in the second quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock valued at $140,000 after buying an additional 2,353 shares during the last quarter. Acrospire Investment Management LLC raised its holdings in shares of Agilent Technologies by 92.3% in the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock valued at $148,000 after buying an additional 1,200 shares during the last quarter. Parallel Advisors LLC raised its holdings in shares of Agilent Technologies by 5.3% in the second quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock valued at $157,000 after buying an additional 131 shares during the last quarter. Finally, Trust Co. of Vermont raised its holdings in shares of Agilent Technologies by 1.8% in the second quarter. Trust Co. of Vermont now owns 2,793 shares of the medical research company’s stock valued at $166,000 after buying an additional 50 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “Agilent Technologies, Inc. (A) Sets New 52-Week High at $65.21” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2017/09/07/agilent-technologies-inc-a-sets-new-52-week-high-at-65-21.html.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.